Economics of Video are Revisited as Next Generation of Codecs Emerge

Previous iterations of the codec narrative have produced predictable outcomes with incremental efficiency gains, gradual deployment, and long-tail coexistence with previous standards. The same is ...
Electronics Weekly

Mouser signs ic-Haus

Among ic-Haus products are: The iC-PZ2656 a high-resolution reflective absolute encoder is a complete lensless optical reflective absolute encoder IC. With its integrated blue LED and interpolator, ...

The 12 Research Papers That Influenced AI Development Over The Last 6 Years

Over the past six years, artificial intelligence has been significantly influenced by 12 foundational research papers. One pivotal moment was the ...
Seeking Alpha

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If ...
Yahoo Finance

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...
Tech Xplore on MSN

Palm-sized piezo robot combines mobility with sub-micrometer positioning accuracy

With the speed at which technology advances, there is little room for suboptimal performance and out-of-date tech. Precise ...
Yahoo Finance

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

OSAKA, Japan & CAMBRIDGE, Mass., February 10, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) ...
The Bakersfield Californian

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

Takeda ( TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
Seeking Alpha

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and ...